Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of REGN10597 alone or with cemiplimab in advanced solid tumors
2025-523399-22-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, open-label trial of REGN10597 and cemiplimab in Nonhematologic neoplasms, melanoma and clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of treatment-emergent adverse events and 5 more. Planned start May 2026; status: authorised.
02
Drugs
REGN10597cemiplimab
03
Conditions
Nonhematologic neoplasmsmelanomaclear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2025-523399-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523399-22-00.